These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33122039)

  • 21. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing expression of Streptococcus pneumoniae surface protein a, PspA: serocross-reactivity within families of antisera induced against clades 1 and 3.
    Silva M; Cabrera-Crespo J; Sbrogio-Almeida ME; Miyaji EN; Ho PL; Leite LC; Lopes AP
    Mol Biotechnol; 2007 Oct; 37(2):146-54. PubMed ID: 17914175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.
    Wang S; Li Y; Shi H; Scarpellini G; Torres-Escobar A; Roland KL; Curtiss R
    Infect Immun; 2010 Jul; 78(7):3258-71. PubMed ID: 20479086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and purification of pneumococcal surface protein a of clade 4 in Escherichia coli using hydroxylapatite and ion-exchange column chromatography.
    Xi H; Yu J; Sun Q; Lu J; Gu T; Guo X; Li B; Chen X; Zhang K; Kong W; Wu Y
    Protein Expr Purif; 2018 Nov; 151():56-61. PubMed ID: 29908315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.
    Brooks-Walter A; Briles DE; Hollingshead SK
    Infect Immun; 1999 Dec; 67(12):6533-42. PubMed ID: 10569772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baculovirus expression, purification and evaluation of recombinant pneumococcal surface adhesin A of Streptococcus pneumoniae.
    De BK; Sampson JS; Ades EW; Johnson SE; Stinson AR; Crook J; Tharpe JA; Huebner RC; Carlone GM
    Pathobiology; 1999; 67(3):115-22. PubMed ID: 10394131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
    J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.
    Piao Z; Akeda Y; Takeuchi D; Ishii KJ; Ubukata K; Briles DE; Tomono K; Oishi K
    Vaccine; 2014 Sep; 32(43):5607-13. PubMed ID: 25132335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.
    Briles DE; Hollingshead S; Brooks-Walter A; Nabors GS; Ferguson L; Schilling M; Gravenstein S; Braun P; King J; Swift A
    Vaccine; 2000 Feb; 18(16):1707-11. PubMed ID: 10689153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of an immunogenic and protective epitope of the PsaA protein of Streptococcus pneumoniae using a phage display library.
    Srivastava N; Zeiler JL; Smithson SL; Carlone GM; Ades EW; Sampson JS; Johnson SE; Kieber-Emmons T; Westerink MA
    Hybridoma; 2000 Feb; 19(1):23-31. PubMed ID: 10768838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease.
    Baril L; Briles DE; Crozier P; King J; Punar M; Hollingshead SK; McCormick JB
    Vaccine; 2004 Dec; 23(6):789-93. PubMed ID: 15542203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.
    Ren B; Szalai AJ; Hollingshead SK; Briles DE
    Infect Immun; 2004 Jan; 72(1):114-22. PubMed ID: 14688088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.
    Arêas AP; Oliveira ML; Miyaji EN; Leite LC; Aires KA; Dias WO; Ho PL
    Biochem Biophys Res Commun; 2004 Aug; 321(1):192-6. PubMed ID: 15358234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS).
    Gor DO; Ding X; Li Q; Sultana D; Mambula SS; Bram RJ; Greenspan NS
    Biol Direct; 2011 Feb; 6():9. PubMed ID: 21306646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.